BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 19657776)

  • 1. Autoantibodies to lens epithelium-derived growth factor/transcription co-activator P75 (LEDGF/P75) in children with chronic nonspecific complaints and with positive antinuclear antibodies.
    Kuwabara N; Itoh Y; Igarshi T; Fukunaga Y
    Autoimmunity; 2009 Sep; 42(6):492-6. PubMed ID: 19657776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigation of the diagnostic value of anti-dense fine speckled 70/lens epithelium derived growth factor p75 autoantibody for autoimmune diseases].
    Türkoğlu G; Berkem R; Karakoç AE
    Mikrobiyol Bul; 2018 Oct; 52(4):413-424. PubMed ID: 30522426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lens epithelium-derived growth factor (LEDGF/p75) expression in fetal and adult human brain.
    Chylack LT; Fu L; Mancini R; Martin-Rehrmann MD; Saunders AJ; Konopka G; Tian D; Hedley-Whyte ET; Folkerth RD; Goldstein LE
    Exp Eye Res; 2004 Dec; 79(6):941-8. PubMed ID: 15642333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-DFS70 antibodies in 597 healthy hospital workers.
    Watanabe A; Kodera M; Sugiura K; Usuda T; Tan EM; Takasaki Y; Tomita Y; Muro Y
    Arthritis Rheum; 2004 Mar; 50(3):892-900. PubMed ID: 15022332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients.
    Okamoto M; Ogawa Y; Watanabe A; Sugiura K; Shimomura Y; Aoki N; Nagasaka T; Tomita Y; Muro Y
    J Autoimmun; 2004 Nov; 23(3):257-66. PubMed ID: 15501396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to the lens and cornea in anti-DFS70-positive subjects.
    Bizzaro N; Tonutti E; Visentini D; Alessio MG; Platzgummer S; Morozzi G; Antico A; Villalta D; Piller-Roner S; Vigevani E
    Ann N Y Acad Sci; 2007 Jun; 1107():174-83. PubMed ID: 17804545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease.
    Muro Y; Sugiura K; Morita Y; Tomita Y
    Lupus; 2008 Mar; 17(3):171-6. PubMed ID: 18372356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases.
    Mahler M; Parker T; Peebles CL; Andrade LE; Swart A; Carbone Y; Ferguson DJ; Villalta D; Bizzaro N; Hanly JG; Fritzler MJ
    J Rheumatol; 2012 Nov; 39(11):2104-10. PubMed ID: 22942262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis.
    Daniels T; Zhang J; Gutierrez I; Elliot ML; Yamada B; Heeb MJ; Sheets SM; Wu X; Casiano CA
    Prostate; 2005 Jan; 62(1):14-26. PubMed ID: 15389814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgE and IgG(4) autoantibodies against DFS70/LEDGF in atopic dermatitis.
    Watanabe K; Muro Y; Sugiura K; Tomita Y
    Autoimmunity; 2011 Sep; 44(6):511-9. PubMed ID: 21329475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-p80 coilin autoantibodies react with a conserved epitope and are associated with anti-DFS70/LEDGF autoantibodies.
    Goto N; Sugiura K; Ogawa Y; Watanabe A; Onouchi H; Tomita Y; Muro Y
    J Autoimmun; 2006 Feb; 26(1):42-51. PubMed ID: 16246523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75.
    Bartholomeeusen K; De Rijck J; Busschots K; Desender L; Gijsbers R; Emiliani S; Benarous R; Debyser Z; Christ F
    J Mol Biol; 2007 Sep; 372(2):407-21. PubMed ID: 17669426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of anti-LEDGF/DFS70 assay matters: a comparative study of six assays.
    Troelnikov A; Hender L; Lester S; Gordon TP; Hughes T; Beroukas D
    Pathology; 2022 Dec; 54(7):910-916. PubMed ID: 36241554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies Against DFS70/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD).
    Seelig CA; Bauer O; Seelig HP
    Clin Lab; 2016; 62(4):499-517. PubMed ID: 27215068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Sensitivity Detection of Anti-DFS70 Antibodies by Radioimmunoprecipitation Assay (RIPA).
    Seelig CA; Blüthner M; Seelig HP
    Clin Lab; 2020 May; 66(5):. PubMed ID: 32390377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders.
    Wu X; Daniels T; Molinaro C; Lilly MB; Casiano CA
    Cell Death Differ; 2002 Sep; 9(9):915-25. PubMed ID: 12181742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the LEDGF/p75 binding site in HIV-1 integrase.
    Busschots K; Voet A; De Maeyer M; Rain JC; Emiliani S; Benarous R; Desender L; Debyser Z; Christ F
    J Mol Biol; 2007 Feb; 365(5):1480-92. PubMed ID: 17137594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and genetic analyses of integrase-interacting proteins lens epithelium-derived growth factor (LEDGF)/p75 and hepatoma-derived growth factor related protein 2 (HRP2) in preintegration complex function and HIV-1 replication.
    Vandegraaff N; Devroe E; Turlure F; Silver PA; Engelman A
    Virology; 2006 Mar; 346(2):415-26. PubMed ID: 16337983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antinuclear antibodies in patients with chronic fatigue syndrome].
    Nishikai M
    Nihon Rinsho; 2007 Jun; 65(6):1067-70. PubMed ID: 17561698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern.
    Dellavance A; Viana VS; Leon EP; Bonfa ES; Andrade LE; Leser PG
    J Rheumatol; 2005 Nov; 32(11):2144-9. PubMed ID: 16265692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.